Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 40, Issue 5, 2007, Pages 461-464

  Gurkan, E ^a   Patah, P A ^a   Saliba, R M ^a   Ramos, C A ^a   Anderson, B S ^a   Champlin, R ^a   de Lima, M ^a   Lichtiger, B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; METHOTREXATE; TACROLIMUS; THROMBOCYTE CONCENTRATE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; BLOOD GROUP ABO SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS;

ACUTE DISEASE; ADULT; AGED; BLOOD PLATELETS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548095971     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705751     Document Type: Article

References (21)

1. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993; 81: 3428-3434.
2. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-4114.
3. Schiffer CA. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev 2001; 15: 175-180.
4. Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001; 41: 766-770.
5. Ishida A, Handa M, Wakui M, Okamoto S, Kamakura M, Ikeda Y. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - a prospective analysis. Transfusion 1998; 38: 839-847.
6. Bock M, Muggenthaler KH, Schmidt U, Heim MU. Influence of antibiotics on posttransfusion platelet increment. Transfusion 1996; 36: 952-954.
7. Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell. Bone Marrow Transplantat 2000; 26: 315-320.
8. Nevo S, Swan V, Enger C, Wojno KJ, Bitton R, Shabooti M et al. Acute bleeding after bone marrow transplantation (BMT) - incidence and effect on survival. A quantitative analysis in 1402 patients. Blood 1998; 91: 1469-1477.
9. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103: 33-339.
10. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and ref-ractoriness to platelet transfusion. N Engl J Med 1997; 337: 1861-1869.
11. Norol F, Bierling P, Roudot-Thoraval F, Le Couer FF, Rieux C, Lavaux A et al. Platelet transfusion: A dose-response study, Blood 1998; 4: 1448-1453.
12. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004; 18: 149-165.
13. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-1456.
14. Klumpp TR, Herman JH, Gaughan JP, Russo RR, Christman RA, Goldberg SL et al. Clinical consequences of alterations in platelet transfusion dose: A prospective, randomized, double-blind trial. Transfusion 1999; 39: 674-681.
15. Brecher ME, Goodnough LT. Clinical consequences of alterations in platelet transfusion dose: A prospective, randomized, double-blind trial (letter). Transfusion 2000; 40: 383.
16. Zeger G, Williams CT, Shulman IA. Single donor platelets: Can we afford to use them? Can we afford not to use them? Transfus Sci 1997; 18: 585-588.
17. Ness PM, Campbell-Lee SA. Single donor versus pooled random donor platelet concentrates. Curr Opin Hematol 2001; 8: 392-396.
18. Brubaker DB, Marcus C, Holmes E. Intravascular and total body equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets. Am J Hematol 1998; 58 165-176.
19. Bishop JF, Matthews JP, Yuen K, McGrath M, Wolf MM, Szer J. The definition of refractoriness to platelet transfusions. Transfusion Med 1992; 2: 35-41.
20. Sweeney JD, Petrucci J, Yankee R. Pooled platelet concentrates: Maybe not fancy, but fiscally sound and effective. Transfus Sci 1997; 18: 575-583.
21. Bernstein SH, Nademanne AP, Vose JM, Tricot G, Fay JW, Negrin RS et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 9: 3509-3517.